Literature DB >> 33575210

Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC.

Adrian von Witzleben1,2, Eve Currall1, Oliver Wood1, Lindsey Chudley1, Oluyemisi Akinyegun3, Jaya Thomas1, Kaïdre Bendjama4, Gareth J Thomas1,3, Peter S Friedmann1, Emma V King1,5, Simon Laban2, Christian H Ottensmeier1,6.   

Abstract

INTRODUCTION: Human papillomavirus 16 (HPV16) is the main cause of oropharyngeal squamous cell carcinoma (OPSCC). To date, the links between HPV16 gene expression and adaptive immune responses have not been investigated. We evaluated the correlation of HPV16 DNA, RNA transcripts and features of adaptive immune response by evaluating antibody isotypes against E2, E7 antigens and density of tumor-infiltrating lymphocytes (TIL).
MATERIAL AND METHODS: FFPE-tissue from 27/77 p16-positive OPSCC patients was available. DNA and RNA were extracted and quantified using qPCR for all HPV16 genes. The TIL status was assessed. Immune responses against E2 and E7 were quantified by ELISA (IgG, IgA, and IgM; 77 serum samples pre-treatment, 36 matched post-treatment).
RESULTS: Amounts of HPV16 genes were highly correlated at DNA and RNA levels. RNA co-expression of all genes was detected in 37% (7/19). E7 qPCR results were correlated with higher anti-E7 antibody (IgG, IgA) level in the blood. Patients with high anti-E2 IgG antibody (>median) had better overall survival (p=0.0311); anti-E2 and anti-E7 IgA levels had no detectable effect. During the first 6 months after treatment, IgA but not IgG increased significantly, and >6 months both antibody classes declined over time. Patients with immune cell-rich tumors had higher levels of circulating antibodies against HPV antigens.
CONCLUSION: We describe an HPV16 qPCR assay to quantify genomic and transcriptomic expression and correlate this with serum antibody levels against HPV16 oncoproteins. Understanding DNA/RNA expression, relationship to the antibody response in patients regarding treatment and outcome offers an attractive tool to improve patient care.
Copyright © 2021 von Witzleben, Currall, Wood, Chudley, Akinyegun, Thomas, Bendjama, Thomas, Friedmann, King, Laban and Ottensmeier.

Entities:  

Keywords:  antibody isotype; gene expression; human papillomavirus 16; immune response; oropharyngeal squamous cell carcinoma

Year:  2021        PMID: 33575210      PMCID: PMC7871909          DOI: 10.3389/fonc.2020.591063

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  51 in total

1.  Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique.

Authors:  Panu Peitsaro; Bo Johansson; Stina Syrjänen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.

Authors:  Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier
Journal:  Nat Immunol       Date:  2017-06-19       Impact factor: 25.606

3.  Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.

Authors:  Feng Wang-Johanning; Danielle W Lu; Yueying Wang; Martin R Johnson; Gary L Johanning
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

4.  The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein.

Authors:  E W Wu; K E Clemens; D V Heck; K Münger
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer.

Authors:  Sri Krishna; Peaches Ulrich; Eric Wilson; Falguni Parikh; Pooja Narang; Shanshan Yang; Amelia K Read; Seunghee Kim-Schulze; Jin G Park; Marshall Posner; Melissa A Wilson Sayres; Andrew Sikora; Karen S Anderson
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

6.  Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.

Authors:  Carole Fakhry; Amanda L Blackford; Geoff Neuner; Weihong Xiao; Bo Jiang; Amit Agrawal; Maura L Gillison
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

7.  Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction.

Authors:  Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden
Journal:  BMC Bioinformatics       Date:  2012-06-18       Impact factor: 3.169

8.  Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.

Authors:  K S Anderson; J Wong; G D'Souza; A B Riemer; J Lorch; R Haddad; S I Pai; J Longtine; M McClean; J LaBaer; K T Kelsey; M Posner
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

9.  The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells.

Authors:  Myriam Gruener; Ignacio G Bravo; Frank Momburg; Angel Alonso; Pascal Tomakidi
Journal:  Virol J       Date:  2007-10-30       Impact factor: 4.099

10.  HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology.

Authors:  Andrew G Schache; Ned G Powell; Kate S Cuschieri; Max Robinson; Sam Leary; Hisham Mehanna; Davy Rapozo; Anna Long; Heather Cubie; Elizabeth Junor; Hannah Monaghan; Kevin J Harrington; Christopher M Nutting; Ulrike Schick; Andy S Lau; Navdeep Upile; Jon Sheard; Kath Brougham; Catharine M L West; Ken Oguejiofor; Steve Thomas; Andy R Ness; Miranda Pring; Gareth J Thomas; Emma V King; Dennis J McCance; Jacqueline A James; Michael Moran; Phil Sloan; Richard J Shaw; Mererid Evans; Terry M Jones
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.